
다중 오믹스 분석과 PISA 기술을 통해 H. pylori에 대한 새로운 항균제 후보물질의 작용 기전을 규명하고 이를 바탕으로 효과적인 다중 표적 항균 치료법 개발이 가능하다.


coremsg

Antimicrobial resistance is responsible for an alarming number of deaths, estimated at 5 million per year. To combat priority pathogens, like Helicobacter pylori, the development of novel therapies is of utmost importance. Understanding the molecular alterations induced by medications is critical for the design of multi-targeting treatments capable of eradicating the infection and mitigating its pathogenicity. However, the application of bulk omics approaches for unraveling drug molecular mechanisms of action is limited by their inability to discriminate between target-specific modifications and off-target effects. This study introduces a multi-omics method to overcome the existing limitation. For the first time, the PISA assay is utilized in bacteria in the PISA-express format to link proteome solubility with different and potentially immediate responses to drug treatment, enabling us the resolution to understand target-specific modifications and off-target effects. This study introduces a comprehensive method for understanding drug mechanisms and optimizing the development of multi-targeting antimicrobial therapies.

### Competing Interest Statement

The authors have declared no competing interest.

Merging Multi-OMICs with Proteome Integral Solubility Alteration Unveils Antibiotic Mode of Action

h-pylori-감염-치료를-위한-새로운-항균제-개발을-위한-다중-오믹스-분석


H. pylori 감염 치료를 위한 새로운 항균제 개발을 위한 다중 오믹스 분석
